Please login to the form below

Not currently logged in
Email:
Password:

Dr Sunita Zalani joins Intarcia Therapeutics as regulatory head

Moves to the Boston company from Onyx Pharmaceuticals
Intarcia Therapeutics Sunita Zalani

Boston-based biopharmaceutical firm Intarcia Therapeutics has appointed Dr Sunita Zalani as vice president, global head of regulatory affairs and quality.

She joins the company from Amgen's Onyx Pharmaceuticals subsiary, where she served as vice president of global regulatory affairs.

Dr Zalani had been with Onyx - which was acquired by Amgen last year - since 2004 and prior to that worked at Lilly as its global regulatory lead.

In her new role at Inarcia, whose most advanced prospect is a phase III version of the diabetes drug exenatide that only needs to be given once a year, Dr Zalani will sit on the leadership team and report directly to chairman, president and CEO Kurt Graves.

He said: "We led a very competitive search for the person who would best meet the steep demands of our global regulatory and quality functions, and I'm delighted Intarcia prevailed as Sunita's choice out of several other simultaneous options she had.

“Her track record shows her to be a team leader with a 'gut grasp' of how to succeed in the biotech industry.”

6th August 2014

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics